{
  "source": "PA-Notification-Siliq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2023 P 1217-8\nProgram Prior Authorization/Notification\nMedication Siliq® (brodalumab)\nP&T Approval Date 5/2017, 5/2018, 2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 7/2023\nEffective Date 10/1/2023;\nOxford: N/A\n1. Background:\nSiliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for\nthe treatment of moderate to severe plaque psoriasis in adult patients who are candidates for\nsystemic therapy or phototherapy and have failed to respond or have lost response to other\nsystemic therapies.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Siliq will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) History of failure or loss of response to other systemic therapies\n-AND-\n(3) Patient is not receiving Siliq in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Siliq will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Siliq therapy\n-AND-\n© 2023 UnitedHealthcare Services, Inc.\n1\n(2) Patient is not receiving Siliq in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, Stelara\n(ustekinumab), Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx\n(secukinumab), Taltz (ixekizumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months\na State mandates may",
    ", Taltz (ixekizumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity, Supply limits and/or Step Therapy may be in place.\n4. Reference:\n1. Siliq [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; April 2020.\nProgram Prior Authorization/Notification – Siliq (brodalumab)\nChange Control\n5/2017 New program.\n5/2018 Annual review with no changes to coverage criteria.\n2/2019 Annual review. Updated background.\n2/2020 Annual review with no changes to coverage criteria.\n2/2021 Annual review. Updated reauthorization duration.\n2/2022 Annual review with no changes to coverage criteria.\n2/2023 Annual review. Updated listed examples from Humira to adalimumab\nand added Rinvoq. Added state mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n© 2023 UnitedHealthcare Services, Inc.\n2"
  ]
}